Do men undergoing sterilizing cancer treatments have a fertile future?
This study was designed to assess the effect of cancer treatments on the natural and assisted reproductive potential of men. A cohort of men with cancer, in whom radiotherapy and/or chemotherapy was planned, were invited to participate. Twenty-two pre- and post-treatment semen samples were analysed. The reproductive potential of participants was assessed with respect to the current range of fertility treatment options available. Abnormal sperm concentrations were found in 27% of patients pre-treatment compared to 68% post-treatment following a mean latency of 20 months from treatment. Fifty-nine percent of patients experienced a clinically significant decrease in sperm, concentration following radiotherapy and/or chemotherapy; 23% developed azoospermia following treatment. Eighty-two percent of patients with testicular malignancy had oligo- or azoospermia post-treatment. Only one patient had a clinically significant reduction in the percentage of motile spermatozoa post-treatment. Cryopreservation of semen prior to treatment improved the fertility prospects of 55% of patients. Intracytoplasmic sperm injection (ICSI) enhanced the fertility prospects of a further 14%. In the absence of, or after depletion of, cryopreserved semen, ICSI could enhance the fertility prospects of 45% of patients. Fertilization has been achieved by ICSI using spermatozoa retrieved by testicular biopsy from an azoospermic testicular cancer survivor 8 years after chemotherapy. It was concluded that chemotherapy and/or radiotherapy may depress semen concentration to the extent of rendering a man infertile. The severity of the reduction in sperm concentration following treatment is unpredictable but likely to be most severe in those with testicular malignancy and those treated with radiotherapy or alkylating chemotherapy agents. Not all men are keen to undergo an appraisal of their post-treatment fertility potential, for reasons which are unclear. Improving awareness and education of patients concerning the effects of both cancer and cancer treatments on reproductive potential is essential. With the advent of ICSI, it is possible to offer a very reasonable chance of conception in all men with cancer who present for cryopreservation of semen prior to treatment in whom spermatozoa (even in very low concentrations) are present in the ejaculate.
Naysmith
T E
TE
fertilityPLUS, National Women's Hospital, Auckland, New Zealand.
Blake
D A
DA
Harvey
V J
VJ
Johnson
N P
NP
D000328:Adult; D001706:Biopsy; D015331:Cohort Studies; D015925:Cryopreservation; D005260:Female; D005298:Fertility; D005307:Fertilization in Vitro / Q000379:methods; D006801:Humans; D007248:Infertility, Male / Q000139:chemically induced / Q000209:etiology*; D008297:Male; D008845:Microinjections; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009845:Oligospermia / Q000209:etiology; D012099:Reproductive Techniques; D012662:Semen Preservation; D013076:Sperm Count; D013081:Sperm Motility; D013094:Spermatozoa; D013736:Testicular Neoplasms / Q000628:therapy; D013737:Testis / Q000473:pathology